Price
No data yet.
Social Signal Score
Revenue
$6.31M-12.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael T. Nally
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 312
- Beta
- -0.14
- Country
- US
Financials
GENB has only 2 quarterly periods on file — the charts below show the full history available.
Revenue
$6.31M-12.6%Net Income
$-67.25MEBITDA
$-63.82MFree Cash Flow
$-58.88MEPS (diluted)
$-0.52Shares Outstanding (diluted)
128.24M+0.0%Operating Expenses
$77.93MCash & Debt
$457.42MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $31.89M | $-203.15M | $-4.98 |
| 2024 | $20.46M | $-173.77M | $-1.68 |
Valuation
GENBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsproactiveinvestors.com·6h ago·Negative
Generate Biomedicines stock jumps as post-IPO lock-up set to expire Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares issued as part of Generate's $400 million initial public offering earlier this year, which included 25 million shares.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.51 per share
Typical surprise -2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.52 vs $-0.51miss
Estimates and results for GENB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.